ResearcherUniversity of CambridgeNo recent work listed
Aarthi Gopinathan
Matched on ORCID iD 0009-0005-5989-025X; OpenAlex author ID A5028394352. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 36
2012: 2 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 7
- Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Co-author DOI 10.1021/acs.analchem.1c04579↗
- Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
- A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.495↗
- mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-0810↗
- GEMMs as preclinical models for testing pancreatic cancer therapies. Co-author DOI 10.1242/dmm.021055↗
- Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20111923↗
- Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1136/gutjnl-2011-300850↗
Closest collaborators
The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Duncan Ian Jodrell · 6 shared papers, 2012–2022 · strength 0.39
- Paper Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multim… DOI 10.1021/acs.analchem.1c04579↗
- Paper Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. DOI 10.1038/s41416-020-0846-2↗
- Paper GEMMs as preclinical models for testing pancreatic cancer therapies. DOI 10.1242/dmm.021055↗
- Owen James Sansom · 3 shared papers, 2015–2022 · strength 0.23
- Paper Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multim… DOI 10.1021/acs.analchem.1c04579↗
- Paper GEMMs as preclinical models for testing pancreatic cancer therapies. DOI 10.1242/dmm.021055↗
- Paper mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. DOI 10.1158/0008-5472.can-16-0810↗
- David Arthur Tuveson · 4 shared papers, 2012–2020 · strength 0.20
- Paper Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. DOI 10.1038/s41416-020-0846-2↗
- Paper A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal… DOI 10.1038/bjc.2017.495↗
- Paper Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. DOI 10.1136/gutjnl-2011-300850↗
- Rebecca J. Brais · 2 shared papers, 2020–2022 · strength 0.18
- Paper Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multim… DOI 10.1021/acs.analchem.1c04579↗
- Paper Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. DOI 10.1038/s41416-020-0846-2↗
- Simon T. Barry · 2 shared papers, 2016–2022 · strength 0.15
- Alan Anthoney · 2 shared papers, 2018–2020 · strength 0.14
- Paper Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. DOI 10.1038/s41416-020-0846-2↗
- Paper A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal… DOI 10.1038/bjc.2017.495↗
- David J. Propper · 2 shared papers, 2018–2020 · strength 0.14
- Paper Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. DOI 10.1038/s41416-020-0846-2↗
- Paper A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal… DOI 10.1038/bjc.2017.495↗
- Daniel H. Palmer · 2 shared papers, 2018–2020 · strength 0.14
- Paper Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. DOI 10.1038/s41416-020-0846-2↗
- Paper A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal… DOI 10.1038/bjc.2017.495↗
- Bristi Basu · 2 shared papers, 2018–2020 · strength 0.14
- Paper Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. DOI 10.1038/s41416-020-0846-2↗
- Paper A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal… DOI 10.1038/bjc.2017.495↗
- Natalie Cook · 3 shared papers, 2012–2018 · strength 0.12
- Paper A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal… DOI 10.1038/bjc.2017.495↗
- Paper Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. DOI 10.1136/gutjnl-2011-300850↗
- Paper Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. DOI 10.1084/jem.20111923↗
- Jennifer P. Morton · 2 shared papers, 2015–2016 · strength 0.12
- Yann Wallez · 1 shared paper, 2022 · strength 0.11
- Brajesh Pratap Kaistha · 1 shared paper, 2022 · strength 0.11
- Charles R. Dunlop · 1 shared paper, 2022 · strength 0.11
- Nicole Strittmatter · 1 shared paper, 2022 · strength 0.11
- Frances M. Richards · 1 shared paper, 2022 · strength 0.11
- Alimu Dayimu · 1 shared paper, 2020 · strength 0.07
- Albrecht Neeße · 1 shared paper, 2020 · strength 0.07
- Harpreet Singh Wasan · 1 shared paper, 2020 · strength 0.07
- Juan W. Valle · 1 shared paper, 2020 · strength 0.07
- Pippa G. Corrie · 1 shared paper, 2020 · strength 0.07
- William P. Steward · 1 shared paper, 2018 · strength 0.06
- Kristopher K. Frese · 2 shared papers, 2012 · strength 0.06
- Jun Qing Yu · 1 shared paper, 2016 · strength 0.05
- Thomas R. Jeffry Evans · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.